Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Non-Current Liabilities (2019 - 2021)

IDEAYA Biosciences (IDYA) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $81.8 million as the latest value for Q3 2021.

  • Quarterly Total Non-Current Liabilities fell 22.78% to $81.8 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $81.8 million through Sep 2021, down 22.78% year-over-year, with the annual reading at $100.0 million for FY2020, 695.6% up from the prior year.
  • Total Non-Current Liabilities hit $81.8 million in Q3 2021 for IDEAYA Biosciences, down from $88.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $105.9 million in Q3 2020 to a low of $11.9 million in Q3 2019.
  • Historically, Total Non-Current Liabilities has averaged $53.1 million across 3 years, with a median of $47.2 million in 2019.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 792.3% in 2020 and later dropped 22.78% in 2021.
  • Year by year, Total Non-Current Liabilities stood at $12.6 million in 2019, then surged by 695.6% to $100.0 million in 2020, then fell by 18.18% to $81.8 million in 2021.
  • Business Quant data shows Total Non-Current Liabilities for IDYA at $81.8 million in Q3 2021, $88.1 million in Q2 2021, and $93.0 million in Q1 2021.